Group 1: Company Announcements - Multiple A-share companies announced operational updates on November 2 [1] - Betta Pharmaceuticals (300558) entered a strategic partnership with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to obtain exclusive general agency rights for a recombinant coagulation factor product [4] - Betta Pharmaceuticals aims to enhance its new drug innovation technology platform and product pipeline through this collaboration, providing support in R&D, clinical trials, production, registration, and sales promotion [4] Group 2: Product Details - Betta Pharmaceuticals' exclusive general agency rights include the recombinant human coagulation factor VIII-Fc fusion protein (FRSW117), which has completed Phase III clinical trials and is intended for patients with Hemophilia A [4] - FRSW117 is classified as a Class 1 therapeutic biological product, with a dosing frequency of once a week for preventive treatment [4] - Currently, no domestic long-acting recombinant factor VIII products have been approved for market release in China [4] Group 3: Financial Contracts - Lanjian Intelligent (688557) signed a significant daily operational contract worth 138 million yuan [5][7] - The contract with Nine Technology (Zhuhai) Co., Ltd. is expected to positively impact the company's performance in 2026 [7] - ST Yifei (688646) announced an overseas procurement order valued at approximately 190 million yuan, accounting for 27.46% of the company's audited revenue for 2024 [8][10]

Core Viewpoint - Multiple A-share companies announced significant operational updates, highlighting strategic partnerships and contracts that may impact their future performance [2][5][6]. Group 1: Company Announcements - Betta Pharmaceuticals (300558) announced a strategic partnership with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to obtain exclusive general agency rights for a recombinant coagulation factor product [2][5]. - The partnership aims to enhance Betta's new drug innovation technology platform and expand its product pipeline, with support in R&D, clinical trials, production, registration, and sales promotion [5]. - Betta's subsidiary, Zhejiang Betta Pharmaceutical Sales Co., Ltd., secured exclusive general agency rights for FRSW117, a long-acting recombinant factor VIII product, in the Greater China region [5]. Group 2: Financial Impact - FRSW117 is designed for the treatment of Hemophilia A (HA) patients, with a dosing frequency of once a week for preventive treatment, and has recently completed Phase III clinical trials [5]. - The product is classified as a Class 1 therapeutic biological product, and no domestic long-acting recombinant factor VIII products have been approved for market release yet [5]. - Lan Jian Intelligent (688557) signed a significant operational contract worth 138 million yuan, which is expected to positively impact the company's performance in 2026 [6][8]. - ST Yifei (688646) announced an overseas procurement order valued at approximately 190 million yuan, representing 27.46% of the company's audited revenue for 2024 [8][11].

Core Viewpoint - The company has entered into a strategic cooperation agreement with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to support the development, industrialization, and commercialization of related products [1][2] Group 1: Strategic Cooperation - The strategic cooperation framework agreement outlines the support the company will provide in research and development, clinical trials, production, registration, and sales promotion [1] - Specific cooperation matters will be detailed in separate agreements between the company and Shengsi Biopharmaceutical [1] Group 2: Market Expansion - The company and its wholly-owned subsidiary aim to enter the recombinant coagulation factor market through this collaboration, aligning with the company's development strategy [2] - The company has obtained exclusive general agency rights for FRSW117 in the Greater China region, which includes mainland China, Hong Kong, Macau, and Taiwan [1]

Group 1 - Company has entered into a strategic cooperation with Jiangsu Shengsi Biological Pharmaceutical Co., Ltd. and Hangzhou Shengsi Biological Pharmaceutical Co., Ltd. to support product development, industrialization, and commercialization [1] - A commercial cooperation agreement has been signed between the company's wholly-owned subsidiary, Zhejiang Beta Pharmaceutical Sales Co., Ltd., and Hangzhou Shengsi Biological, granting exclusive distribution rights for FRSW117 in Greater China [1] - The strategic cooperation framework agreement is a preliminary agreement, with specific cooperation details to be outlined in subsequent agreements, and it is not expected to have a significant impact on the company's 2025 financial results [1] Group 2 - The collaboration aims to enter the recombinant coagulation factor market, further expanding the company's product portfolio in line with its development strategy [2]

Core Viewpoint - Beida Pharmaceutical has entered into a strategic cooperation with Shengsi Biotech to enhance its new drug innovation technology platform and expand its product pipeline [1] Group 1: Strategic Cooperation - The strategic cooperation aims to leverage the strengths of both companies to support each other and promote mutual development [1] - The partnership will focus on expanding into the restructured blood products market to better meet clinical needs and strengthen the company's product matrix [1] Group 2: Financial Overview - For the year 2024, Beida Pharmaceutical's revenue composition is projected to be 100% from pharmaceutical manufacturing [1] - As of the report date, Beida Pharmaceutical has a market capitalization of 23.9 billion yuan [1]

Core Viewpoint - Beida Pharmaceutical has entered into a strategic cooperation with Shengsi Bio to enhance its new drug innovation technology platform and expand its product pipeline [1] Group 1: Strategic Cooperation - The strategic cooperation framework agreement aims to leverage the strengths of both companies for mutual support and development [1] - Beida Pharmaceutical has signed a commercial cooperation agreement with Shengsi Bio, granting exclusive distribution rights for the product FRSW117 in the Greater China region [1] Group 2: Product Development - FRSW117 is a long-acting recombinant factor VIII product, classified as a type of therapeutic biological product, which has recently completed Phase III clinical trials [1] - The product is intended for routine prophylaxis, on-demand treatment, and perioperative bleeding management for hemophilia A patients, with a dosing frequency of once a week for preventive treatment [1] - Currently, there are no domestically approved long-acting recombinant factor VIII products available in the market [1]

证券代码：300558 证券简称：贝达药业 公告编号：2025-071 贝达药业股份有限公司 关于与晟斯生物达成战略合作暨签署《商业合作协议》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、贝达药业股份有限公司（以下简称"贝达药业"或"公司"）与江苏 晟斯生物制药有限公司（以下简称"江苏晟斯生物"）、杭州晟斯生物制药 有限公司（以下简称"杭州晟斯生物"，与"江苏晟斯生物"并称"晟斯生 物"）达成战略合作，签署《战略合作框架协议》，贝达药业将在研发、临 床、生产、注册及销售推广等环节给予晟斯生物支持，助推相关产品的研发、 产业化和商业化。《战略合作框架协议》为双方协商的框架性协议，就具体 合作事项，公司与晟斯生物将另行签署协议做出约定，该事项对公司2025年 度经营成果不构成重大影响。本协议自双方签字、盖章之日起生效。 2、公司全资子公司浙江贝达医药销售有限公司（以下简称"贝达医药销 售"）与杭州晟斯生物签署《杭州晟斯生物制药有限公司与浙江贝达医药销 售有限公司之商业合作协议》（以下简称"《商业合作协议》"），贝达医 药销售取得注射用培重 ...

Core Viewpoint - Beida Pharmaceutical has entered into a strategic cooperation with Jiangsu Shengsi Biopharmaceutical Co., Ltd. and Hangzhou Shengsi Biopharmaceutical Co., Ltd. to enhance its new drug innovation technology platform and expand its product pipeline [1] Group 1: Strategic Cooperation - The strategic cooperation aims to leverage the strengths of both parties to support mutual development [1] - A framework agreement has been signed to facilitate this collaboration [1] Group 2: Market Expansion - The partnership is focused on broadening the treatment areas and restructuring the blood product market [1] - This initiative is intended to better meet clinical needs and strengthen the company's product matrix [1] Group 3: Commercial Agreement - Beida Pharmaceutical has signed a commercial cooperation agreement with Hangzhou Shengsi Biopharmaceutical, granting exclusive distribution rights for the FRSW117 product in the Greater China region [1]

Core Viewpoint - The 2025 National Medical Insurance Directory negotiations are ongoing, focusing on pricing discussions for innovative drugs, particularly in the chronic disease medication sector [1] Group 1: Negotiation Details - The third day of the national negotiations began at approximately 1:40 PM, with participation from companies such as Novartis, Gensai, Roche, and Betta Pharmaceuticals [1] - The morning session emphasized negotiations on chronic disease medications, with Eli Lilly and Sinopharm bringing significant products to the discussions [1]

Core Viewpoint - Beida Pharmaceutical is a leading company in the domestic cancer drug research and development sector, focusing on innovative drug development with a strong technical team and a rich product line [1] Financial Performance - For Q3 2025, Beida Pharmaceutical reported revenue of 2.717 billion yuan, ranking 26th among 110 companies in the industry, with the industry leader, East China Pharmaceutical, generating 32.664 billion yuan [2] - The net profit for the same period was 303 million yuan, placing the company 28th in the industry, while the top performer, Hengrui Medicine, achieved a net profit of 5.76 billion yuan [2] Profitability and Debt Ratios - As of Q3 2025, Beida Pharmaceutical's debt-to-asset ratio was 38.97%, slightly up from 38.81% year-on-year, exceeding the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 80.34%, down from 83.81% year-on-year, but still above the industry average of 57.17% [3] Executive Compensation - The chairman, Ding Lieming, received a salary of 2.6508 million yuan in 2024, a decrease of 250,000 yuan compared to 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 7.99% to 29,500, while the average number of circulating A-shares held per account increased by 8.68% to 14,200 [5] Business Highlights - For the first three quarters of 2025, Beida Pharmaceutical achieved a revenue growth of 15.90% year-on-year, while the net profit decreased by 23.86% [6] - The company is seeing progress in its overseas expansion, with the eye drug EYP-1901 entering phase 3 clinical trials and sales of Ensartinib in the U.S. beginning to ramp up [6] - New products in the domestic market, such as recombinant human serum albumin and CDK4/6 inhibitor, are expected to contribute to revenue growth [6] Future Projections - Revenue projections for 2025, 2026, and 2027 are 3.569 billion yuan, 4.537 billion yuan, and 5.561 billion yuan, respectively, with net profits of 506 million yuan, 727 million yuan, and 921 million yuan [6] - The company is expected to maintain a "buy" rating with a target price of 77.71 yuan per share for 2026, based on a PE ratio of 45 times [6]